These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 18042288)

  • 1. Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study.
    Parhofer KG; Münzel F; Krekler M
    Cardiovasc Diabetol; 2007 Nov; 6():36. PubMed ID: 18042288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U; Bramlage P; Paar WD; Thoenes M; Unger T
    Cardiovasc Diabetol; 2007 Apr; 6():12. PubMed ID: 17407587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes.
    Sowers JR; Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Weber MA;
    J Clin Hypertens (Greenwich); 2006 Jul; 8(7):470-80. PubMed ID: 16849900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of initial blood pressure and comorbidity for the efficacy of a fixed combination of an angiotensin receptor blocker and hydrochlorothiazide in clinical practice.
    Schmieder RE; Schwertfeger M; Bramlage P
    Vasc Health Risk Manag; 2009; 5():991-1000. PubMed ID: 19997579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of irbesartan/HCTZ in severe hypertension according to cardiometabolic factors.
    Franklin SS; Neutel JM
    J Clin Hypertens (Greenwich); 2010 Jul; 12(7):487-94. PubMed ID: 20629810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: a secondary analysis of the irbesartan/hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study.
    Saunders E; Cable G; Neutel J
    J Clin Hypertens (Greenwich); 2008 Jan; 10(1):27-33. PubMed ID: 18174768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of olmesartan vs irbesartan on metabolic parameters and visfatin in hypertensive obese women.
    De Luis DA; Conde R; Gonzalez Sagrado M; Aller R; Izaola O; Perez Castrillon JL; Romero E; Castro MJ
    Eur Rev Med Pharmacol Sci; 2010 Sep; 14(9):759-63. PubMed ID: 21061834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
    O'Brien E; Barton J; Nussberger J; Mulcahy D; Jensen C; Dicker P; Stanton A
    Hypertension; 2007 Feb; 49(2):276-84. PubMed ID: 17159081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fixed-dose combination of zofenopril plus hydrochlorothiazide vs. irbesartan plus hydrochlorothiazide in hypertensive patients with established metabolic syndrome uncontrolled by previous monotherapy. The ZAMES study (Zofenopril in Advanced MEtabolic Syndrome).
    Napoli C; Omboni S; Borghi C;
    J Hypertens; 2016 Nov; 34(11):2287-97. PubMed ID: 27653164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on Irbesartan or Irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Aug; 147(31-32):43. PubMed ID: 16128197
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients.
    Strutz F; Bramlage P; Paar WD
    Curr Med Res Opin; 2005 Sep; 21(9):1433-40. PubMed ID: 16197662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care.
    Bramlage P; Pittrow D; Kirch W
    Curr Med Res Opin; 2004 Oct; 20(10):1625-31. PubMed ID: 15462695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
    Neutel JM; Franklin SS; Lapuerta P; Bhaumik A; Ptaszynska A
    J Hum Hypertens; 2008 Apr; 22(4):266-74. PubMed ID: 17928878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone.
    Derosa G; Fogari E; D'Angelo A; Cicero AF; Salvadeo SA; Ragonesi PD; Ferrari I; Gravina A; Fassi R; Fogari R
    J Clin Pharm Ther; 2007 Jun; 32(3):261-8. PubMed ID: 17489878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.